TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17420365
Drug: Intracameral injection
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intracameral injection
Study: 14633177
Drug: Induction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment with a daily dose of 5 MU of IFN‐alpha2b for 4 weeks, followed by 5 MU three times a week with ribavirin (1000‐1200 mg/day, according to weight) until completing 1 year of treatment.
Study: 14633177
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of IFN‐alpha2b of 3 MU three times per week for 48 weeks together with ribavirin (1000‐1200 mg/day, according to weight).
Study: 14633177
Drug: Induction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment in patients with genotype 1 and elevated viral load (>2 x 10(6) copies/ml).
Study: 14633177
Drug: Induction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment compared to standard treatment regarding dropouts and side effects.
Study: 1550038
Drug: Breakfast treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breakfast treatment (three meals per day)
Study: 1550038
Drug: No-breakfast treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-breakfast treatment (two meals per day)
Study: 3993543
Drug: Propranolol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (160 to 320 mg/day)
Study: 3993543
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 to 200 mg/day)
Study: 25316430
Drug: Polyherbal formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyherbal formulation (500 mg, twice daily)
Study: 15784709
Drug: GH by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH by sc injection six times per week (0.30 mg/kg.wk)
Study: 15784709
Drug: Control (C),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (C), no GH treatment
Study: 11840368
Drug: Simvastatin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (5 mg/day, increased to maximum 20 mg/day if non-HDL > 135 mg/dL)
Study: 27791311
Drug: Topical minoxidil
Normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical minoxidil 5% solution
Study: 30944142
Drug: 2% chlorhexidine-alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% chlorhexidine-alcohol for skin preparation before catheter insertion
Study: 30944142
Drug: 5% povidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% povidone iodine-alcohol for skin preparation before catheter insertion
Study: 24243886
Drug: rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 20 mg/d
Study: 19929371
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for CDI
Study: 9675657
Drug: Interferon treatment
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon treatment with N-acetyl-cysteine
Study: 9675657
Drug: Interferon treatment
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon treatment without N-acetyl-cysteine
Study: 8016036
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum (2 mg), chewed ad libitum
Study: 2605867
Drug: Triple-hormone combination
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple-hormone combination (adrenaline, cortisol, glucagon)
Study: 22880820
Drug: Thalidomide 100
Normalized name: thalidomide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide 100 mg once a day for 14 days
Study: 8083708
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy and surgical resection
Study: 8083708
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy with > or = 90% necrosis and postoperative chemotherapy
Study: 8083708
Drug: Poor response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Poor response to preoperative chemotherapy and/or lack of postoperative chemotherapy
Study: 2572182
Drug: Loratadine 0.11-0.24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine 0.11-0.24 mg/kg once daily
Study: 2572182
Drug: Dexchlorpheniramine 0.10-0.23
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexchlorpheniramine 0.10-0.23 mg/kg every 8 hours
Study: 803831
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition with hyperosmolar glucose (10.5 gm nitrogen, 2,340 kilocalories/day)
Study: 803831
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition with hyperosmolar glucose (5.9 gm nitrogen, 1,600 kilocalories/day)
Study: 30361241
Drug: 8-week once-weekly
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-week once-weekly regimen of rifapentine plus isoniazid
Study: 27473688
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for cannabis cessation (1-hour sessions once a week for 16 weeks, in addition to pharmacological treatment)
Study: 27473688
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (psychoeducation + pharmacological treatment)
Study: 15939408
Drug: Testosterone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (0.5 mg)
Study: 12902802
Drug: Monotherapy postpartum
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monotherapy postpartum
Study: 12902802
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy postpartum
Study: 12902802
Drug: Highly active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly active antiretroviral therapy postpartum
Study: 8780817
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) therapy
Study: 12902802
Drug: Stable therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable therapy
Study: 1516491
Drug: Beef insulin
Normalized name: Beef insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beef insulin (B)
Study: 1516491
Drug: Sulfated beef
Normalized name: Beef
DrugBank: Beef (DB10509)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfated beef insulin (SB)
Study: 1516491
Drug: Pork insulin
Normalized name: Pork insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pork insulin (P)
Study: 9212308
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (H)
Study: 2981652
Drug: Metkephamid (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metkephamid (50 mg intramuscularly)
Study: 7860754
Drug: CD4 binding
Normalized name: CD4 IgG
DrugBank: Recombinant human CD4 immunoglobulin G (DB17812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD4 binding site antibodies
Study: 6127095
Drug: Epoprostenol (PGI2)
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoprostenol (PGI2) 1 and 2 ng/ml
Study: 6127095
Drug: Atropine 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.04 mg/kg i.v.
Study: 6127095
Drug: Atenolol 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 0.2 mg/kg i.v.
Study: 6127095
Drug: Propranolol 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 0.2 mg/kg i.v.
Study: 29855175
Drug: Adalimumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (40 mg every other week)
Study: 15236989
Drug: Platelet-activating factor
Normalized name: Platelet-activating factor acetyltransferase
DrugBank: Platelet Activating Factor (DB02261)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-activating factor (PAF) treatment during IUI
Study: 9717591
Drug: i.t. sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.t. sufentanil plus 2.5 mg plain bupivacaine (Group B)
Study: 10641571
Drug: GM-CSF injected
Normalized name: axatilimab-csfr Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF injected intradermally into a single dermal metastasis and into a normal skin site for 10 consecutive days at one of four dose levels (10, 20, 40, or 80 microg/injection)
Study: 6582073
Drug: Isotretinoin administered
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin administered 1 hour before a meal
Study: 6582073
Drug: Isotretinoin administered
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin administered concomitantly with a meal
Study: 6582073
Drug: Isotretinoin administered
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin administered 1 hour after a meal
Study: 6582073
Drug: Isotretinoin administered
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin administered during a complete fast
Study: 6582073
Drug: Isotretinoin administered
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin administered with food
Study: 23210735
Drug: Peri-incisional triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peri-incisional triamcinolone acetonide (PITMC) injection
Study: 19889502
Drug: MMD procedural
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: MMD procedural preparation (MMD-PP)
Study: 11886474
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg plus amoxicillin 1 g and clarithromycin 500 mg (Group A, n = 46)
Study: 11886474
Drug: Bismuth subcitrate
Normalized name: BISMUTH SUBCITRATE
DrugBank: Bismuth subcitrate potassium (DB09275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subcitrate 125 mg plus tetracycline 500 mg and furazolidone 200 mg (Group B, n = 46)
Study: 11886474
Drug: No resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: No resistance to clarithromycin or amoxicillin
Study: 8344690
Drug: n-IL-2 therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-IL-2 therapy
Study: 3755051
Drug: Brl 20627
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brl 20627 (10 mg)
Study: 24885187
Drug: trastuzumab-containing neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: trastuzumab-containing neoadjuvant therapy
Study: 18776819
Drug: Glycerol (oral)
DrugBank: Glycerin (DB09462)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycerol (oral)
Study: 18776819
Drug: Glycerol (oral)
DrugBank: Glycerin (DB09462)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycerol (oral) + Dexamethasone (intravenous)
Study: 18776819
Drug: Dexamethasone (intravenous)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (intravenous)
Study: 12906021
Drug: Oral Valganciclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Valganciclovir
Study: 12906021
Drug: Intravenous Ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Ganciclovir
Study: 10589650
Drug: Ulinastatin (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin (5000 U/kg) administered 2 min before vecuronium (0.1 mg/kg)
Study: 8886680
Drug: Hartmanns solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hartmanns solution
Study: 1281726
Drug: Terazosin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (10 mg/d)
Study: 6374804
Drug: 750-ml collapsible
Normalized name: BREATHERITE SPACER COLLAPSIBLE BR200
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750-ml collapsible spacer
Study: 30672174
Drug: Acupuncture A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture A group (Tongdu Tiaoshen acupuncture, daily treatment)
Study: 30672174
Drug: Acupuncture B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture B group (Tongdu Tiaoshen acupuncture, treatment every other day)
Study: 30672174
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (nimodipine tablets, 30 mg three times daily)
Study: 12393368
Drug: Remifentanil 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 3 micro g kg(‐1) h(‐1)
Study: 12393368
Drug: Propofol 1
Normalized name: propofol 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1 mg kg(‐1) h(‐1)
Study: 10457148
Drug: Oral folic
Normalized name: folic acid Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral folic acid (5 mg daily for six weeks)
Study: 2120769
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg naproxen daily for a week
Study: 2120769
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg naproxen daily for a week
Study: 2120769
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of 750 mg and 1000 mg naproxen
Study: 911007
Drug: Daily drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily drug reminder chart with concurrent pharmacist supervision
Study: 28784312
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and fluorouracil (CF); two 3-weekly cycles of cisplatin [80 mg/m2 intravenously on day 1] and fluorouracil [1 g/m2 per day intravenously on days 1-4]
Study: 28784312
Drug: Epirubicin, cisplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin, cisplatin, and capecitabine (ECX); four 3-weekly cycles of epirubicin [50 mg/m2], cisplatin [60 mg/m2], and capecitabine [1250 mg/m2 daily throughout the four cycles]
Study: 20705516
Drug: Artesunate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate (100 mg) with sulfalene (250 mg) plus pyrimethamine (12.5 mg) for 3 days
Study: 20705516
Drug: Praziquantel (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (40 mg/kg per day)
Study: 15842977
Drug: JTT-705 600
Normalized name: JTT-251
DrugBank: JTT-251 (DB18174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JTT-705 600 mg
Study: 12895217
Drug: Dimethylpolysiloxane, sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimethylpolysiloxane, sodium bicarbonate and pronase (treatment C)
Study: 12895217
Drug: Dimethylpolysiloxane alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimethylpolysiloxane alone (treatment A)
Study: 12895217
Drug: Dimethylpolysiloxane plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimethylpolysiloxane plus sodium bicarbonate (treatment B)
Study: 10526276
Drug: Concurrent thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent thoracic irradiation (50 grays in 20 fractions, initiated after the second cycle of chemotherapy)
Study: 10526276
Drug: Alternating thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating thoracic irradiation (20 grays in 8 fractions followed by 15 grays in 6 fractions, scheduled between chemotherapy cycles)
Study: 6121577
Drug: Diacetolol 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diacetolol 200 mg/day
Study: 6121577
Drug: Diacetolol 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diacetolol 400 mg/day
Study: 6121577
Drug: Diacetolol 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diacetolol 800 mg/day
Study: 19077889
Drug: Intraoperative surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative surfactant treatment (bovine surfactant at a dose of 20 mg phospholipids/kg)
Study: 19077889
Drug: Intraoperative surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative surfactant treatment
Study: 8892713
Drug: CEE plus
Normalized name: Ecee Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE plus medroxyprogesterone acetate (MPA), 10 mg/d for 12 d/mo
Study: 8892713
Drug: CEE plus
Normalized name: Ecee Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE plus MPA, 2.5 mg/d daily
Study: 8892713
Drug: CEE plus
Normalized name: Ecee Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE plus micronized progesterone (MP), 200 mg/d for 12 d/mo
Study: 6681024
Drug: Minoxidil (5-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minoxidil (5-40 mg/day)
Study: 6681024
Drug: Hydralazine (25-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine (25-200 mg/day)
Study: 30623821
Drug: Family-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused therapy (FFT-A)
Study: 28269582
Drug: Progressive abduction
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive abduction loading therapy
Study: 21042013
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium bicarbonate (increasing dose until serum total CO(2) ≥ 24 mM)
Study: 21042013
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (same medications, no sodium bicarbonate)
Study: 16697413
Drug: Sertraline with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline with transdermal estrogen (ET)
Study: 16697413
Drug: Sertraline with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline with placebo
Study: 10235440
Drug: 5.1 g
Normalized name: POVIDONE-IODINE 5.1 g in 1 L TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.1 g n-3 FA daily for 6 months
Study: 10235440
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g n-3 FA daily for another 4 weeks (after initial treatment)
Study: 7022037
Drug: Cimetidine and
Normalized name: Cimetidine and sodium alginate only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine and glucagon combination
Study: 31389157
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg daily oral modified release morphine
Study: 26991683
Drug: Nurses who
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurses who reported being 'somewhat comfortable' referring patients to CAM therapies
Study: 26991683
Drug: Nurses who
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurses who reported being 'very comfortable' referring patients to CAM therapies
Study: 26991683
Drug: Nurses with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurses with formal CAM education referring patients to CAM therapies
Study: 22844698
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium diet (0.34 g/kg)
Study: 22844698
Drug: Medium sodium
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium sodium diet (1.34 g/kg)
Study: 22844698
Drug: High sodium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sodium diet (2.82 g/kg)
Study: 19602953
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia (combination of one of four hypnotic drugs supplemented by one of four opioids)
Study: 15269071
Drug: No influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: No influenza vaccine (Control)
Study: 12477513
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drugs (group B; n = 16) for 4 months
Study: 12477513
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drugs for 2 months, followed by carnitines for 2 months (group C; n = 26)
Study: 12477513
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory treatment given concomitantly with carnitines (group D; n = 26) for 4 months
Study: 9822455
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg of the ACE inhibitor enalaprilat
Study: 2696937
Drug: proxibarbal (Ipronal
Approvals — FDA: no, EMA: no, PMDA: no
Description: proxibarbal (Ipronal "Polfa") 50 mg tablets, administered one tablet twice daily for 6 weeks every quarter over 3 years
Study: 2696937
Drug: placebo tablets,
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets, administered one tablet twice daily for 6 weeks every quarter over 3 years
Study: 22741442
Drug: Tamoxifen 10
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 10 mg bid
Study: 798626
Drug: Tamoxifen 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 15 mg/m2 bid
Study: 18990678
Drug: Budesonide (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (low-dose inhaled corticosteroid)
Study: 14986244
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and oral clinafloxacin treatment for native valve infection
Study: 14986244
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and oral clinafloxacin treatment for prosthetic valve endocarditis (PVE)
Study: 11380230
Drug: Combined chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemotherapy and radiotherapy (CRT)